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angioplasty in critical limb ischemia
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Stefano Gennai, MD,a Giovanni Coppi, MD,c Luigi Marcheselli, BA,d and Gioacchino Coppi, MD,a
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Objective: The goal of this article is to report the preliminary results of infrapopliteal percutaneous transluminal angio-
plasty stenting with the Nile Croco coronary bifurcated stent (Minvasys, Gennevilliers, France) for selected patients with
critical limb ischemia (CLI).
Methods: From October 2006 to December 2010, 31 patients with CLI with below-the-knee TransAtlantic Inter-Society
Consensus C and D lesions at the popliteal (n[ 17, 54.8%) and distal tibioperoneal trunk (n[ 14, 45.2%) bifurcations,
with suboptimal primary percutaneous transluminal angioplasty results (residual stenosis >30%, elastic recoiling, or
dissection), with at least two-vessel runoff to the foot (present or after percutaneous transluminal angioplasty), free of
aortoiliac arterial disease, and at high surgical risk (more than three risk factors) were treated with the Nile Croco
coronary bifurcated stent. Study end points included technical success, immediate and midterm primary and secondary
patency rates, clinical improvement, and limb salvage.
Results: Technical success was achieved in all patients (100%) without any intraoperative complications. Early compli-
cations included an acute stent occlusion and an acute compartment syndrome for a collateral arterial branch perforation.
Median follow-up was 12.1 months (range, 1-32). Primary and secondary patency rates were 96.7% and 86.2% (95%
conﬁdence interval [CI], 67.2%-94.6%) at 30 days and and 100% and 96.6% (95% CI, 78.0%-99.5%) at 1 year, respec-
tively. Clinical improvement (an upward shift of at least two Rutherford categories) was achieved in 28 patients (90.3%).
A major amputation was required in one patient (3.2%). The overall limb salvage rate at 1 year was 96.7% (95% CI, 78.6%-
99.5%).
Conclusions: Preliminary data suggest that the Nile Croco bifurcated stent for below-the-knee angioplasty in selected
patients with CLI is associated with high rates of technical success, early and midterm patency, and clinical improvement.
Limb salvage rates are acceptable for this technically highly challenging anatomy, yet further studies with larger patient
populations are necessary to validate these results. (J Vasc Surg 2013;57:1006-13.)Infrapopliteal percutaneous transluminal angioplasty
(PTA) for the treatment of critical limb ischemia (CLI) is
now considered an effective treatment and an established
alternative to traditional surgical techniques.1-4 An attempt
at angioplasty before primary amputation or surgical bypass
in patients at high surgical risk is recommended.4,5However,
PTA is associated with low procedural success and high
restenosis rates, with 3-year patency rates around 25%.6
New developments in equipment and techniques have led
to continuous improvements in PTA technical and clinical
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6residual stenosis, postdilatation arterial dissections, elastic
recoil, and early thrombosis of treated segments persists.7
Therefore, stenting for below-the-knee (BTK) treatment is
increasingly being used. Recent studies on straight in-line
arterial ﬂow BTK treatment quote high clinical success
rates>96%3 and1-year patency rates around75%—amarked
improvement compared with the 68.6% for PTA alone
reported in the same study.8 A meta-analysis comprising
640 patients treated with PTA stenting reported an in-
stent restenosis rate of 25.7% at 1 year.9
BTK atherosclerotic lesions at bifurcations, however,
prove to be technically more challenging; increase the
risk of plaque shift to the side branch, stent thrombosis,
and recurrent stenosis involving the main vessels or, more
commonly, the side branch of bifurcated lesions. Addition-
ally, main vessel patency is often achieved at the expense of
the side branch, where restenosis rates remain relatively
high.10
Materials and techniques for percutaneous coronary
interventions (PCIs) have been developed to meet similar
anatomical challenges in small-diameter vessels.11 The
authors hypothesized that these dedicated materials could
also be applied to the endovascular treatment of infrapopli-
teal bifurcated lesions.
Hence, this study was prospectively designed to assess
the safety and effectiveness, in terms of immediate and
midterm outcomes, of a coronary bifurcated stenting
Table I. Patient clinical and lesion characteristics
Number of patients 31
Male/female ratio 21/10
Age, years, mean (range) 71.6 (45-91)
Risk factors, number (%)
Diabetes mellitus 25 (80.6%)
Hypertension 18 (58%)
Cardiac insufﬁciency (NYHA >I) 16 (51.6%)
Preexisting renal insufﬁciency
(creatinine level >2 mg/dL)
11 (35.5%)
Chronic renal insufﬁciency
(requiring dialysis)
4 (36.4%)
Dislipidemia (cholesterol >120 mg/dL) 9 (29%)
Current smoker 5 (16%)
Chronic obstructive lung disease 3 (9.7%)
High risk (>3 risk factors) 31 (100%)
Lesion classiﬁcation
Stage III (Fontaine)/category 4 (Rutherford) 2 (6.4%)
Stage IV (Fontaine)/category 5-6
(Rutherford)
29 (93.5 %)
Lesion location and classiﬁcation, number (%)
Popliteal bifurcation 17 (54.8%)
TASC C 11 (64.7%)
TASC D 6 (35.3%)
Tibioperoneal trunk 14 (43.2%)
TASC C 8 (57.1%)
TASC D 6 (42.9%)
Ankle brachial index, mean 6 SD 0.42 6 0.15
Toe brachial index, mean 6 SD 0.42 6 0.03
NYHA, New York Heart Association functional class; SD, standard devia-
tion; TASC, TransAtlantic Inter-Society Consensus; TASC C, stenoses 1-4
cm, occlusions 1-2 cm, and extensive stenoses at the tibial trifurcation;
TASC D, occlusions >2 cm and diffuse tibial vessel disease.
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Genevilliers, France) for infrapopliteal angioplasty at tibial
bifurcations in selected patients with CLI.
METHODS
Ethical approval for this study was not required at this
institution.
Treatment protocol and patient selection. From
January 2006 to December 2010, 816 patients with CLI
were admitted to the Department of Vascular Surgery,
Nuovo Ospedale Civile S. Agostino-Estense Baggiovara,
and assessed for peripheral endovascular procedures. CLI
was considered to be categories 4-6 according to the Ruth-
erford classiﬁcation,12 evidenced as rest pain, nonhealing
ulceration or gangrene that could requiremajor amputation,
plus evidence of diffuse pedal ischemia, resting ankle
pressure <60 mm Hg, and toe pressure <30 mm Hg.13,14
All patients were preoperatively assessed with duplex
ultrasound (DUS) scanning and submitted to angiography.
All vascular lesions were classiﬁed according to the modiﬁed
TransAtlantic Inter-Society Consensus (TASC) classiﬁca-
tions for tibioperoneal occlusive disease.14 A total of
325 patients with TASC C (stenoses 1-4 cm, occlusions
1-2 cm, and extensive stenoses at the tibial trifurcation)
and D (occlusions >2 cm and diffuse tibial vessel disease)
tibial lesions, mainly associated with multilevel lower limb
disease, were treated with BTK angioplasty; of these, 97
patients were affected by isolated tibial disease—52 with
PTA alone and 45 with PTA/stenting (in the case of subop-
timal primary angioplasty results consisting of residual
stenosis >30%, elastic recoil, or ﬂow-limiting dissection).
Patients with CLI with lesions at the infrapopliteal or
tibioperoneal trunk bifurcations (n ¼ 31) with at least
two-patent-vessel runoff to the foot (present or after PTA
distal to the related bifurcation), without aortoiliac arterial
disease, and at high surgical risk (more than three risk
factors) were selected for endovascular treatment with the
Nile Croco bifurcated stent. Primary PTA was performed
proximally or distally to the ostium of the bifurcation
only and never in the bifurcation. In patients with inade-
quate runoff (less than two-patent-vessel runoff to the
foot) after PTA revascularization, main vessel treatment
only was performed, and according to previous stent indi-
cations, straight stents were used (n ¼ 14).These patients
were excluded from the current study.
In the same period, a total of 318 good-risk patients
with CLI who had chronic long or total femoropopliteal
occlusions or had failed attempted endovascular interven-
tions were treated with bypass surgery; 125 included tibial
bypass.
Data for all patients were prospectively collected in
a computer database and retrospectively analyzed. Baseline
demographic and clinical data are reported in Table I.
Procedure details. All patients were admitted to the
vascular surgery department 1 day prior to the preprog-
rammed intervention, femoral access and run-in feasibility
were assessed with DUS scanning, and ankle brachial index
(ABI) and toe brachial index (TBI) measurements weretaken. All endovascular interventions were performed in
a dedicated angiographic room equipped with a C-Arm
(OEC 9800; GE Medical System, Salt Lake City, Utah),
intravascular ultrasound (IVUS, Eagle Eye Gold; Volcano
Therapeutics, Rancho Cordova, Calif), and a DUS scanner
(Esaote AU 5, Genova, Italy). In cases of multilevel disease
in other lower limb locations, the extreme distal lesions
were treated ﬁrst. All procedures were performed under
local anesthesia. Ipsilateral antegrade percutaneous access
was used in 21 cases (67.7%) and retrograde contralateral
percutaneous access in crossover in the remaining
10 patients (32.3%). Introducer sheaths (Cordis, Miami,
Fla) ranged from 5F to 6F, with crossover procedures
treated preferentially with a 6F reinforced introducer
sheath (Accuﬂex Bipore, Northvale, NJ). A standardized
endovenous bolus of 5000 IU of unfractionated heparin
was administered systematically.
Prior to endovascular treatment, diagnostic angiog-
raphy was performed to quantify lesion extent (Fig 1).
All infrapopliteal stenoses and occlusions were crossed
with a 0.014-inch (Asahi Grand Slam PTCA guidewire;
Abbott Vascular, Abbott Park, Ill) or 0.035-inch guidewire
(Terumo Medical, Somerset, NJ).
Materials and interventional bifurcated stenting
technique. The Nile Croco bifurcated stent is a balloon-
expandable chromium-cobalt bare metal stent with a short
scaffold at the side port to provide coverage of the side-
branch ostium and allow access to the side branch. The
Fig 2. The Nile Croco chromium-cobalt bare-metal bifurcated
stent with a short scaffold side port.
Fig 1. Preoperative angiographic image of an obtsructive lesion at
the tibial bifurcation and inferior popliteal artery.
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(Fig 2). It is a single-operator device with independent
catheter manipulation and pressure monitoring. The
system allows for a strategy of main-branch stenting with
optional side-branch stenting.
The system has two independent balloons (ranging in
diameter from 2.5 to 3.5 mm for the main branch and
from 2.0 to 3.0 mm for the side branch), which each
have a rapid exchange lumen for the required two guide-
wires. The system requires a 6F guiding catheter (inner
diameter $0.70 inch). The stent is divided into three cell
design segments to create the same metal/artery ratio
along the bifurcation and avoid cell overstretching. The
system allows ﬁnal kissing-balloon inﬂation in both the
main and side branches.
The standard deployment procedure involves initial
wiring (0.014-inch guidewire) of both the main- and
side-branch vessels and advancement of the stent device
over the lesion (Fig 3, A). The main-branch balloon is
inﬂated and the bifurcated stent is deployed (Fig 3, B).
The side-branch balloon can then be inﬂated (Fig 3, C
and D). The delivery system is then removed (Fig 3, E).
Additional treatment of the side branch, with additional
balloon inﬂation or stent implantation, can be performed
directly (Fig 4). The indications for stent implantation in
the side branch were the presence of lesions not completely
covered by the bifurcated stent side port.
Postoperative angiography conﬁrmed technical success
(Fig 5).
Postinterventional patient management. Postinter-
ventional anticoagulation therapy included a dual-antiplate-
let-aggregation regimen comprising 75 mg of clopidogrel
and 100 mg of acetylsalicylic acid per day for 4 weeks,
followed by at least one of these drugs indeﬁnitely. Antith-rombotic prophylaxis (low-molecular-weight heparin) was
administered during the period of bed conﬁnement (usually
around 3 weeks) for concomitant wound therapy, according
to the American College of Chest Physician Guidelines.15
This center follows a wound care therapy algorithm
already outlined by Alexandrescu et al.16,17
Outcome assessment and follow-up. Technical
success was determined as less than 30% of ﬁnal residual
stenosis measured at the narrowest point of the treated
segment. Patency was deﬁned as the absence of recurrent
occlusion causing more than 50% reduction in diameter of
the treated segment, as documented by DUS scanning or
angiography. A 50% stenosis was identiﬁed by DUS scan-
ning when a peak systolic velocity of$200 cm/s developed
and a 3:1 velocity ratio was seen across the lesion.
Ankle brachial index was evaluated both before and
after revascularization procedures; in patients in whom
Fig 3. A, Advancement of the stent device over the lesion. B, Main branch balloon inﬂation for stent deployment.
C, Advancement of the side branch balloon. D, Side-branch balloon inﬂation. E, Delivery system removal.
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recorded. Clinical improvement was achieved if there was
a $0.10 increase in ABI and wound healing produced
improvement of at least two Rutherford categories.12
Primary and secondary patency rates, limb salvage, and
amputation-free survival were deﬁned according to recom-
mended standards.18
Follow-up consisted of a clinical examination and DUS
scanning at 1, 3, 6 and 12 months and biannually thereafter.
Angiographic examinations were performed in selected
patients with no observed clinical improvement and/or sus-
pected restenosis or occlusion.
Study end points. Preliminary end points of this study
were technical success, 30-day and 1-year primary and
secondary patency rates, clinical improvement, and limb
salvage. Secondary end points were intra- and post-
operative complications and overall and amputation-free
survival.
Statistical analysis. Quantitative data are expressed as
mean values and standard deviations, and categorical data,
as frequencies. Amputation-free survival was measured
from the date of surgery to the date of last follow-up or
the date of major amputation. Overall survival was deﬁned
from the date of surgery to the date of last observation or
death resulting from any cause. Survival curves were
calculated using Kaplan-Meier estimates, and 95% conﬁ-
dence intervals (CIs) with Greenwood’s formula. Theincidence rate was deﬁned as the ratio of observed events to
overall person-years of follow-up, or person-years of
follow-up in speciﬁed intervals of time. Continuous vari-
ables were compared with the t-test.
RESULTS
Technical success was achieved in all cases (100%) as
documented at ﬁnal angiography. The Croco Nile bifur-
cated stent was deployed in all cases, and side-branch
extensions were added in 19 cases (61.3%; Fig 4). No intra-
operative complications were recorded. Operative data are
outlined in Table II.
Study outcomes are provided in Table III. Immediate
complications included one repeat PTA and percutaneous
thromboaspiration at postoperative day 1 because of an
acute occlusion of the stent at the popliteal bifurcation. A
reintervention was also required for acute compartment
syndrome associated with a collateral branch perforation
of the posterior tibial artery. The patient was returned to
the operating room and treated with a covered stent, fas-
ciotomy, and surgical drainage of the hematoma. Another
patient required proximal stenting and distal PTA to
improve runin and runoff. Other complications included
access site hematoma (n ¼ 2) and persistence of chronic
renal insufﬁciency (n ¼ 1).
The mean follow-up was 12.1 months (range, 1-32).
Recurrent in-stent restenosis was evidenced in three
Table II. Operative details
General operative details
Access
Ipsilateral (percutaneous þ Proglidea) 25 (81)
Contralateral 6 (19)
Additional bifurcation extension segments 19
Preplanned additonal procedures in other locationsb 44
Iliac 1
Superﬁcial femoral arteryc 9
Popliteald 7
Below the knee 27
Concurrent procedures
AngioSculpte 2
Intravenous ultrasound imaging 2
Filter 1
aProglide, Abbott Vascular, Abbott Park, Ill.
bPercutaneous transluminal angioplasty with or without stenting.
cOf which one double adsorbable stent in the superﬁcial femoral artery was
deployed and one debulking with the Rotarex system (Straub Medical AG,
Stardubstrasse, Switzerland) þ percutaneous transluminal angioplasty
because of popliteal intrastent restenosis and multiple stenosis at the level of
the superﬁcial femoral artery.
dOne covered stent for popliteal aneurysm.
eAngioSculpt, AngioScore, Fremont, Calif.
Table III. Major and minor amputations during the
follow-up period to 12 months
Variable 30 days 3 months 6 months 12 months
Patients, No. 31 29 23 16
Amputation, No. (%)
Minor 3 (9.7) 2 (6.7) 3 (12) 3 (16)
Major — 1 (3.3) — —
Fig 4. Postoperative angiographic image of the bifurcated stent
and the side-branch extension deployed.
Fig 5. Final angiogram conﬁrming technical success.
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procedure, and was successfully treated with intrastent
repeat PTA; one drug-eluting balloon (Dior; Eurocor
Gmbh, Bonn, Germany) and two cutting balloons (Angio-
sculpt; Angioscore, Fremont, Calif) were employed.
Secondary procedures were necessary in three cases
(9.7%) for distal stenosis in the peroneal artery also treated
with PTA; in one patient, proximal PTA on the superﬁcial
femoral and popliteal arteries was necessary to improve
inﬂow at 2 months, and in the other two patients withdiffuse atherosclerotic disease of the tibial vessels, additional
distal PTA and stenting procedures were performed to
increase runoff at 3 and 4 months from the initial procedure
(Table III).
Primary patency rates (Fig 6) were 96.7% and 86.2% at
30 days and 12 months, respectively (95% CI, 67.2%-
94.6%; standard error [SE], 6.4%; 10.5 [95% CI, 3.9-
28.0]  100 person-years). Secondary patency (Fig 7)
was 100% and 96.6% at 30 days and 12 months, respec-
tively (95% CI, 78.0%-99.5%; SE, 3.4%; 8.5 [95% CI,
2.7-26.2]  100 person-years).
Considerable clinical improvement of the entire patient
cohort was noted as reﬂected by a signiﬁcant increase in the
ABI (preintervention, 0.42 6 0.15; postintervention,
0.736 0.12) and TBI (preintervention, 0.426 0.03; post-
intervention, 0.79 6 0.09) measured 12 to 24 hours after
stent deployment (P < .001).
An improvement of at least two Rutherford categories
was achieved in 28 patients (90.3%). Preplanned minor
amputations were required in 13 patients (41.9%). A major
amputation was necessary in a single patient only (3.2%) at
2 months.
The overall limb salvage rate was 96.7% (95% CI,
78.6%-99.5%; SE, 3.3%; 2.4 [95% CI, 0.3-17.2]  100
Fig 6. Overall primary patency for selected high-risk patients with
critical limb ischemia (CLI) and lesions at the tibioperoneal
bifurcations treated with the Nile Croco bifurcated stent.
Fig 7. Overall secondary patency for selected high-risk patients
with critical limb ischemia (CLI) and lesions at the tibioperoneal
bifurcations treated with the Nile Croco bifurcated stent.
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survival at 12 months was 96% (95% CI, 77%-99%).
Six patients (19.4%) died during the follow-up period.
The overall survival rate (Fig 9) at 12 months was 79.3%
(95% CI, 59.5%-90.1%; SE, 7.9%; 16.1 [95% CI, 7.7-
33.7]  100 person-years).
DISCUSSION
Percutaneous transluminal angioplasty in infrapopliteal
lesions is associated with acceptable clinical beneﬁt, tech-
nical success, and rates of patency, limb salvage, and
morbidity19-21 but is plagued by complications throughout
follow-up, such as high rates of recurrent stenosis, low
primary patency rates, and amputations that question the
subsequent durability of the procedure.3,4
Stent implantation, an already established treatment for
iliac arterial occlusive disease,22 was therefore employed in
the tibial district. However, the small vessel diameter of
tibial arteries and the prevalence of calciﬁed and diffuse
atherosclerotic disease have both been associated with
low procedural success and higher restenosis rates3,6,8,23
and, therefore, pose many challenges to PTA stenting.
With advances in endovascular therapy and technolo-
gies, together with the development of speciﬁcally designed
materials for infrapopliteal arteries,24-26 such as absorbable,
carboﬁlm-coated, and coronary drug-eluting stents,6,27,28
interest in primary and secondary stent-supported BTK
angioplasty for CLI has increased. In a meta-analysis pub-
lished in 2008 with 640 patients with predominantly
straight in-line arterial ﬂow treatment, the primary patency
rate was 78.9%, the limb salvage rate was 96.4%, and Ruth-
erford class improved in 91.3%.9 The report concluded that
the results are encouraging for selected patients, particu-
larly those affected with diabetes.9,29-35
As studies dedicated to the BTK bifurcation are lacking
in the literature, this study must be compared with results
achieved in in-line arterial ﬂow treatments, although the
technical difﬁculty posed by the natural bifurcation is
elevated because of increased risks of plaque shift to theside branch, stent thrombosis, and recurrent stenosis
involving the main vessels or, more commonly, the side
branch of bifurcated lesions. The incidences of these
complications are difﬁcult to estimate, because to our
knowledge, dedicated data are unavailable in literature.
Additionally, main vessel patency is often achieved at the
expense of the side branch, where restenosis rates remain
relatively high.36 The incidence of BTK lesions at the bifur-
cation can only be estimated, as there are no data in the
literature. However, coronary artery disease bifurcation
lesions have been estimated to account for up to 15% of
patients treated with percutaneous coronary intervention.10
A variety of double-stent strategies have been devel-
oped for the treatment of both the main vessel and the
branch in bifurcation coronary lesions: simultaneous kiss-
ing Y, V, and T; crush; reverse-T; and culotte techniques
(with varying degrees of overlap between the stents).11
These techniques aim to achieve maximal apposition to
the vessel wall but, as yet, have not yielded an improved
clinical proﬁle when compared with simple strategies,
and randomized controlled trials have not yet been un-
dertaken.10,37
These ongoing limitations underline the necessity for
dedicated materials for BTK bifurcated lesions. Now three
main types of stents dedicated to bifurcation treatment are
commercially available36: preformed stents with side ports
to facilitate access to the side branch after main vessel treat-
ment, conical stents that follow the anatomical geometry of
the ostium, and stents designed to treat the side branch
ﬁrst.
At this center, prior to 2006, patients with lesions at the
tibial bifurcations were treated with PTA, surgical bypass,
straight vessel stenting close to the bifurcation but not
over the ostium, or, in nine cases, the kissing-balloon tech-
nique.11,38-40 The results were unsatisfactory, and alterna-
tive techniques were considered. Hence, in 2006, while
awaiting the development of dedicated BTK bifurcated
lesion materials, technologies already available and in use
for coronary artery bifurcation treatment were considered.
Fig 8. Overall limb salvage for 31 high-risk patients with tibio-
peroneal bifurcated lesions treated with the Nile Croco bifurcated
stent.
Fig 9. Overall survival for high-risk patients with tibioperoneal
bifurcated lesions treated with the Nile Croco bifurcated stent.
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in this series on the basis of the availability of poststenting
kissing-balloon dilatation, optional side-branch stenting,
the bifurcated stent structure (assumed by the authors
to offer increased stability compared with straight in-line
stenting or other two-stent techniques), and low balloon
proﬁles (2-3.5 mm).
The treatment proposed in this study is appropriate for
varying kinds of bifurcated lesions; the lesion is crossed by
guidewires, with the possibility of choosing which tibial
vessel should be restored throughout the main body and
preserving direct access to the secondary vessel through
the side branch.
Although technically demanding, technical success in
this study was achieved in all (100%) patients. The two
cases of complications were assumed to be linked to incom-
plete stent expansion in one case and device advancement
in a complicated anatomy in the other. Despite issues
linked to a learning curve, this study reports results at
1 year that are comparable to, if not more advantageous
than, those reported in literature for in-line arterial ﬂow
BTK stenting: a 9.7% in-stent restenosis rate compared
with an average of 25%9 and an 86.2% primary patencyrate compared with an average of 76%.8,9 The high patency
rates thereafter supported a high incidence of clinical
improvement and a single major amputation at 12 months.
Limb salvage in this study was also comparable, reporting
a 96.7% vs a 96.4% recorded in the previously described
meta-analysis.9
The major limitation of the present study is that it is
a retrospective analysis of a prospectively designed, non-
randomized small patient cohort, without a comparative
control group. Further, as limited outcome data are avail-
able in the literature regarding the treatment of BTK bifur-
cated lesions, comparisons with other treatment techniques
are difﬁcult to make. Therefore, comparisons have been
made with straight in-line arterial ﬂow BTK outcomes,
even though the treatment outlined in this study is techni-
cally and anatomically more complicated.
CONCLUSIONS
These preliminary data represent high rates of technical
success, early and midterm patency rates, and clinical
improvement for selected patients with BTK bifurcated
lesions treated with the Nile Croco bifurcated stent.
Limb salvage rates are acceptable for this technically highly
challenging anatomy, yet further studies with larger patient
populations are necessary to validate the results.
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